Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: A multidisciplinary expert statement

American Journal of Medicine

Volumn 110, Issue 1 SUPPL. 1, 2001, Pages S79-S100

  Hawkey, Christopher J ^a   Lanas, Angel I ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; CYCLOOXYGENASE 2 INHIBITOR; LANSOPRAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE;

CANCER PREVENTION; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG USE; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; MEDICAL SPECIALIST; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; ULCER HEALING;

EID: 0035825146     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00651-3     Document Type: Review

References (241)

1. Consensus development methods, and their use in clinical guideline development
2. The management of Helicobacter pylori infection in primary care
3. The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care
4. An evidence-based appraisal of reflux disease management
5. Ibuprofen and acetaminophen in the relief of acute pain: A randomized double-blind placebo-controlled study
6. Postoperative analgesia with IV propacetamol and ketoprofen combination after disc surgery
7. Treating acute pain in hospital
8. Efficacy of minor analgesics in primary dysmenorrhoea: A systematic review
9. North of England evidence based guideline development project: Summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis
10. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee
11. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients. A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalga
12. Comparison of an antiinflammatory dose of ibuprofen an analgesic dose of ibuprofen and acetaminophen in the treatment of patients with osteoarthritis of the knee
13. Clinical response of OA patients who use acetaminophen when randomised to rofecoxib or ibuprofen
14. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases
15. Review of dose-response studies of NSAIDs in rheumatoid arthritis
16. Ibuprofen versus other non-steroidal anti-inflammatory drugs: Use in general practice and patient perception
17. Postoperative analgesia with IV propacetamol and ketoprofen combination after disc surgery
18. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: A randomized, double-blind single-dose study
19. Naproxen and paracetamol compared with naproxen only in coxarthrosis. Increased effect of the combination in 18 patients
20. Additive effect of combined naproxen and paracetamol in rheumatoid arthritis
21. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer
22. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
23. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
24. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration
25. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
26. n of 1 trials in osteoarthritis - Study was conceptually and statistically biased
27. The PAIN Study: Paracetamol aspirin and ibuprofen new tolerability study. A large-scale randomised clinical trial comparing the tolerability of aspirin ibuprofen and paracetamol for short-term analgesia
28. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen
29. Effects of acetaminophenon human gastric mucosal injury caused by ibuprofen
30. Analgesic ingestion and chronic peptic ulcer
31. Smoking, nonsteroidal anti-inflammatory drugs, and acetaminophen in gastric ulcer. A study of associations and of the effects of previous diagnosis on exposure patterns
32. Aspirin, paracetamol, and haematemesis and melaena
33. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: A case-control study
34. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding
35. The comparative effects of paracetamol and indomethacin on renal function in healthy female volunteers
36. Acute effects of paracetamol on prostaglandin synthesis and renal function in normal man and in patients with renal failure
37. Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man
38. 2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis
39. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease
40. n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis
41. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction
42. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
43. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An under recognized public health problem
44. Colorectal cancer risk chronic illnesses operations and medications: Case control results from the Melbourne colorectal cancer study
45. Aspirin use and reduced risk of fatal colon cancer
46. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
47. Nonsteroidal antiinflammatory drugs and colorectal cancer
48. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals
49. Aspirin non-steroidal anti-inflammatory drugs and protection from colorectal cancer: A review of the epidemiological evidence
50. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia
51. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women
52. Colorectal cancer and nonsteroidal anti-inflammatory drugs
53. Aspirin and gastrointestinal cancer
54. Effect of antiinflammatory drugs on overall risk of common cancer: A case-control study in general practice research data base
55. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study
56. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester Minnesota. 1980 through 1984
57. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
58. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
59. Risk of Alzheimer's disease and duration of NSAID use
60. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up
61. Ranitidine in the treatment of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulcers
62. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer
63. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
64. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs
65. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study
66. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol
67. A guideline for the treatment and prevention of NSAID-induced ulcers
68. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin
69. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: Interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications - Future research needs
70. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy
71. Helicobacter pylori eradication in patients taking non-steroidal, anti-inflammatory drugs: The HELP NSAIDs Study
72. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study
73. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat
74. Prescribing of nonsteroidal anti-inflammatory drugs in general practice: Determinants and consequences
75. Quantitative estimation or rare adverse events which follow a biological progression. A new model applied to chronic NSAID use
76. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
77. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville
78. Cost of NSAID adverse effects to the UK National Health Service
79. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy
80. Konsequenzen und Kosten der NSA-Gastropathie in Deutschland
81. Overall mortality among patients surviving an episode of peptic ulcer bleeding
82. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs
83. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs
84. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized double-blind placebo-controlled trial
85. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates
86. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons
87. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use
88. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study
89. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
90. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
91. Epidemiology of NSAID induced gastrointestinal complications
92. Incidence of upper gastrointestinal perforations, symptomatic ulcers and bleeding (PUBS). Rofecoxib compared to NSAIDs
93. Comparison of upper gastrointestinal toxicity in rofecoxib and naproxen in patients with rheumatoid arthritis
94. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs
95. Non-steroidal anti-inflammatory drugs and ulcers: Facts and figures multiply, but do they add up?
96. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis
97. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs
98. Variability in the risk of major gastrointestinal complications from non-aspirin non-steroidal anti-inflammatory drugs
99. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease
100. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
101. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
102. Efficacy of 12 months misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial
103. Risk factors associated with refractory peptic ulcers
104. Non-steroidal anti-inflammatory drugs and ulcer complications: A risk factor analysis for clinical decision-making
105. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial
106. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation
107. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
108. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs
109. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation: An overview of epidemiological studies published in the 1990s
110. COX-2 inhibitors
111. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
112. Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis
113. The cyclooxygenase-2 inhibitors: Safety and effectiveness
114. Rofecoxib [Vioxx, MK-0966;4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
115. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats
116. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
117. Management of nonsteroidal anti-inflammatory drug-related peptic ulcer bleeding
118. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs
119. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs
120. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study
121. Peptic ulcer bleeding in the elderly: Relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs
122. Helicobacter pylori increases the risk of peptic ulcer bleeding: A case-control study
123. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding
124. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly. A case-control study
125. Interaction of risk factors for peptic ulcer bleeding
126. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users
127. H pylori infection increases the risk of non-steroidal anti-inflammatory drug (NSAID)-induced gastro-duodenal ulceration
128. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
129. Can eradication of Helicobacter pylori prevent future development of peptic ulcers in patients receiving long-term continuous nonsteroidal anti-inflammatory drugs
130. Eradication of Helicobacter pylori does not prevent ulcer relapse in patients with NSAIDs-induced gastric ulcer
131. Effect of rofecoxib on endoscopic ulcers in osteoarthritis patients: Analysis of potential risk factors
132. Influence of H. pylori infection and/or low dose aspirin on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDs
133. Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori
134. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
135. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer
136. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
137. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs
138. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs
139. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed
140. Non-steroidal drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
141. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
142. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays
143. Rofecoxib
144. Preliminary study of the safety and efficacy of SC-58635 a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects
145. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
146. Analgesic efficacy and plasma levels of a highly selective inhibitor of COX-2 (SC-58635) in patients with post-surgical dental pain
147. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
148. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
149. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
150. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
151. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
152. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomised, clinical trial in patients with osteoarthritis of the knee and hip
153. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin of ibuprofen
154. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
155. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
156. Decisions loom on selective COX-2 inhibitors
157. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial
158. Are there differences among nonsteroidal anti-inflammatory drugs?
159. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
160. The COX-2 specific inhibitor rofecoxib was effective in the treatment of postorthopedic surgical pain
161. Dose ranging trial of the effect of rofecoxib in primary dysmenorrhoea
162. COX-2 specific inhibition with MK-0966 or 50mg qd over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg tid
163. COX-2 specific inhibition with MK-0966 25 or 50 mg QD does does not increase intestinal permeability: A controlled study with placebo and indomethacin 50 mg TID
164. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OS) and rheumatoid arthritis (RA) patients as compared to NSAIDs
165. Influence of H. pylori and other potential risk factors on clinical GI events in a double-blind outcome study of rofecoxib vs naproxen
166. Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomised controlled trial
167. Treatment with rofecoxib required less gastrointestinal (GI) co-medication and fewer GI procedures than nonspecific cyclooxygenase inhibitors
168. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
169. Renal side effects of cyclo-oxygenase-type-2 inhibitor use
170. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease
171. Are COX-2 inhibitors nephrotoxic?
172. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
173. Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs
174. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression
175. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use
176. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly
177. Silent peptic ulceration: Deadly silence or golden silence?
178. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to nonsteroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis
179. Significance of dyspeptic symptoms during healing and maintenance of NSAID-associated gastroduodenal lesions with omeprazole misoprostol and ranitidine
180. Gastric mucosal injury by fatty acid and acety-salicylic acids
181. Gastrointestinal tolerability of the COX-2 inhibitor, meloxicam, in osteoarthritis patients: The meloxicam large scale international study safety assessment (MELISSA)
182. Improvement in gastrointestinal tolerability of the selective COX-2 inhibitor, meloxicam, compared with piroxicam: Results of the safety and efficacy large scale evaluation of COX inhibiting therapies (SELECT) trial in osteoarthritis
183. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis
184. Treatment of endoscopy-negative NSAID induced upper gastrointestinal symptoms with cimetidine: An international multicentre collaborative study
185. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: An international multicentre collaborative study
186. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis
187. A randomized controlled trial of aspirin in persons recovered from myocardial infarction
188. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study
189. Randomised trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2
190. Randomised trial of prophylactic daily aspirin in British male doctors
191. Aspirin, heparin or both to treat acute unstable angina
192. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Interim results
193. Final report on the aspirin component of the ongoing Physicians Health Study
194. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
195. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
196. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results
197. A prospective study of aspirin use and primary prevention of cardiovascular disease in women
198. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: Clinical evidence from the Physicians Health Study
199. Low-dose aspirin therapy for chronic stable angina. A randomized placebo-controlled clinical trial
200. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
201. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
202. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
203. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy
204. European stroke prevention study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
205. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
206. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
207. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations
208. Adverse effects of low-dose aspirin in a healthy elderly population
209. Prophylactic aspirin and risk of peptic ulcer bleeding
210. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - Analysis of gastrointestinal bleeding during the UK-TIA trial
211. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product
212. Evidence of aspirin use in both upper and lower gastrointestinal perforation
213. Aspirin: New cardiovascular uses for an old drug
214. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
215. Aspirin and the risk of colorectal cancer in women
216. Aspirin use and chronic diseases: A cohort study of the elderly
217. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
218. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study
219. Aspirin use, cancer and polyps of the large bowel
220. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal anti-inflammatory drugs: A pooled analysis of published studies and a new population based study
221. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis
222. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP)
223. Extent, mode, and dose dependence of anticancer effects
224. 2 blocking drugs
225. Risk of Alzheimer's disease and duration of NSAID use
226. Clinical trial of indomethacin in Alzheimer's disease
227. A double-blind placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
228. 2 blocking drugs and the risk for Alzheimer's disease: The Rotterdam Study
229. 2 receptor antagonists: The Cache County Study
230. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine
231. Separation of aspirin's impairment of haemostasis from mucosal injury in the human stomach
232. Schutzwirkung von omeprazol gegenüber niedrig dosierter acetylsalicylsäure. Endoskopisch kontrollierte doppelblindstudie an gesunden probanden
233. Prospective randomized trial of H. pylori eradication versus maintenance omeprazole to prevent recurrent upper gastrointestinal hemorrhage in high-risk aspirin and non-aspirin NSAID users
234. Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low dose aspirin: A cohort study
235. Helicobacter pylori increases the risk of gastrointestinal bleeding in patients taking low dose aspirin
236. Is Helicobacter pylori infection a risk or protective factor for mucosal lesions development in patients chronically treated with acetylsalicylic acid?